Bharat, GSK to halve price of malaria vaccine by 2028

25/6/2025 17:45

Drugmakers Bharat Biotech and GSK will cut the price of their malaria vaccine to below $5 per dose by 2028, more than halving its current cost, they said on Wednesday.



The vaccine, Mosquirix or RTS,S, was developed by GSK and the non-profit PATH, and was the first malaria vaccine to get approval from the World Health Organization in 2022.



GSK is working on a technology transfer to Bharat, and will continue to supply the adjuvant part of the vaccine to Bharat when the Indian drugmaker fully takes over production of the shot by 2028.



A phased reduction in price of the vaccine will begin immediately, GSK said in a statement with Bharat, reaching the target price of below $5 by 2028.



The price cut was "driven by process improvements, expanded production capacity, cost-effective manufacturing, and minimal profit margins," the statement read.



The other approved malaria vaccine, developed by the University of Oxford and the Serum Institute of India, is priced at under $4 a dose.